Important Update on Cediranib development for Alveolar Soft Part Sarcoma (ASPS)
Dear ASPS community. Many of our patients who participated in Cediranib clinical trials reported on
Yosef
February 4, 2012
Dear ASPS community. Many of our patients who participated in Cediranib clinical trials reported on
Please note the two Phase II clinical trials available for ASPS patients in the
Dear ASPS Community, We are very happy to report the opening of another clinical trial
Scientists from the group of Dr. Massimo Loda reported the results of an extensive study
Cediranib (Recentin, AZD2171) is an inhibitor of VEGF (Vascular Endothelial Growth Factor) receptors. Therefore, the
The GVAX cancer vaccine clinical trial, which has been opened in January 2006 is no
ArQule Achieves Clinical Milestone in MiT Trial with ARQ 197 Thursday October 2, 8:01 am
Previously, we reported that Alveolar Soft Part Sarcoma is a candidate for therapy by drugs
Update on the ARQ 197 Clinical Trial (November 23): The new clinical trial (read below)
Dear ASPS community. As you probably know, the GVAX cancer vaccine clinical trial has been
Designed with ❤️ by Studio Luxmeo | Developed by Yoav Levavi